Announcements Trials

Browse Landscape

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 13 Observational 1 Expanded_access 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

nilotinib 5 dabrafenib 4 Nivolumab 4 Afatinib 4 trametinib 3 regorafenib 3 midostaurin 3 elotuzumab 3 TIC10 compound 3 Sunitinib 3 Prednisone 3 Capecitabine 3 Abiraterone Acetate 3 3-Iodobenzylguanidine 3 venetoclax 2 tucatinib 2 tempol 2 tazemetostat 2 talquetamab 2 talimogene laherparepvec 2 ruxolitinib 2 pomalidomide 2 olaparib 2 niraparib 2 leronlimab 2 lenvatinib 2 ibrutinib 2 gilteritinib 2 ceritinib 2 brexucabtagene autoleucel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Expanded_access × lazertinib × Clear all

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Yuhan Corporation

Approved for marketing

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡